While Viking Therapeutics Inc has overperformed by 3.80%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VKTX fell by -60.14%, with highs and lows ranging from $81.86 to $18.92, whereas the simple moving average fell by -44.69% in the last 200 days.
On April 08, 2025, Goldman started tracking Viking Therapeutics Inc (NASDAQ: VKTX) recommending Neutral. A report published by Scotiabank on February 13, 2025, Initiated its previous ‘Sector Outperform’ rating for VKTX. Citigroup also rated VKTX shares as ‘Neutral’, setting a target price of $38 on the company’s shares in an initiating report dated February 07, 2025. B. Riley Securities initiated its ‘Buy’ rating for VKTX, as published in its report on November 22, 2024. H.C. Wainwright’s report from November 04, 2024 suggests a price prediction of $102 for VKTX shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Overweight’.
Analysis of Viking Therapeutics Inc (VKTX)
Viking Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -14.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 44.25, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and VKTX is registering an average volume of 4.61M. On a monthly basis, the volatility of the stock is set at 9.22%, whereas on a weekly basis, it is put at 6.43%, with a gain of 9.36% over the past seven days. Furthermore, long-term investors anticipate a median target price of $90.26, showing growth from the present price of $25.94, which can serve as yet another indication of whether VKTX is worth investing in or should be passed over.
How Do You Analyze Viking Therapeutics Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.95%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 73.29% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
VKTX shares are owned by institutional investors to the tune of 73.29% at present.
